Want to see HK:7666 full AI Analyst Report?
7666 Stock Chart & Stats
$18.52
$0.67(3.75%)
―
--
Day’s Range― - ―
52-Week Range$9.46 - $29.98
Previous CloseN/A
VolumeN/A
Average Volume (3M)9.48M
Market Cap
HK$21.90B
Enterprise Value$15.05B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,083,110,100
10 Day Avg. Volume10,048,264
30 Day Avg. Volume9,477,528
Financial Highlights & Ratios
PEG Ratio3.01
Price to Book (P/B)24.28
Price to Sales (P/S)247.19
P/FCF Ratio-185.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.71Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin RecoveryThe sharp 2025 revenue rebound, alongside a substantial gross-margin recovery, indicates stronger commercial performance and improved economics of delivered products. If sustained, this combination can expand the contribution available to fund operating expenses and support progress toward eventual breakeven.
Balance Sheet RepairA return to positive equity and materially lower leverage strengthen the company’s financial foundation. This reduces balance-sheet pressure, improves resilience while biotechnology investments continue, and gives management greater flexibility to allocate capital toward products and development.
Reduced Cash BurnAlthough cash generation remains negative, the narrower operating and free-cash-flow deficit versus 2024 suggests some improvement in cash discipline or operating efficiency. Continued progress would extend funding capacity and reduce the pace at which the company must seek external capital.
Bears Say
Severe Operating LossesThe company remains far from operating breakeven despite better revenue and gross margin. Extremely negative operating margins indicate that selling, research, or other operating costs still overwhelm gross profit, limiting the likelihood that near-term growth alone will produce sustainable earnings.
Persistent Cash BurnNegative operating and free cash flow show that the business is not self-funding its activities. Continued cash outflows can consume financial resources over the next several quarters and increase reliance on external funding, even after the balance sheet’s leverage improvement.
Weak Shareholder ReturnsNegative earnings and negative return on equity indicate that the repaired capital structure has not yet translated into productive shareholder returns. Until profitability improves, retained capital may continue to generate weak outcomes and limit the company’s ability to compound value internally.
Metis TechBio Co., Ltd. Class H News
7666 FAQ
What was Metis TechBio Co., Ltd. Class H’s price range in the past 12 months?
Metis TechBio Co., Ltd. Class H lowest stock price was $9.46 and its highest was $29.98 in the past 12 months.
What is Metis TechBio Co., Ltd. Class H’s market cap?
Metis TechBio Co., Ltd. Class H’s market cap is HK$21.90B.
When is Metis TechBio Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Metis TechBio Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Metis TechBio Co., Ltd. Class H overvalued?
According to Wall Street analysts Metis TechBio Co., Ltd. Class H’s price is currently Undervalued.
Does Metis TechBio Co., Ltd. Class H pay dividends?
Metis TechBio Co., Ltd. Class H does not currently pay dividends.
What is Metis TechBio Co., Ltd. Class H’s EPS estimate?
Metis TechBio Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Metis TechBio Co., Ltd. Class H have?
Metis TechBio Co., Ltd. Class H has 1,083,110,100 shares outstanding.
What happened to Metis TechBio Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Metis TechBio Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:7666
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Metis TechBio Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
Metis TechBio Co., Ltd. Class H
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
7666 Stock 12 Month Forecast
Average Price Target
$18.71
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
―